Case report: A patient with Delayed Sleep-Wake Phase Disorder and Optic Nerve Hypoplasia treated with tasimelteon: a case study

• Published in: Frontiers in neuroscience Vol. 17; p. 1287514
• Main Authors: Smieszek, Sandra P., Kaden, Alyssa R., Johnson, Caroline E., Brzezynski, Jennifer L., Xiao, Changfu, Polymeropoulos, Christos M., Birznieks, Gunther, Emsellem, Helene A., Polymeropoulos, Mihael H.
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Research Foundation 14.11.2023; Frontiers Media S.A
• Subjects: biological rhythms; Circadian rhythm; circadian rhythm disorders; clinical trials research; delayed sleep; Delayed Sleep-Wake Phase Disorder; Drug dosages; Hypoplasia; Medicine; Melatonin; Neuroscience; Optic nerve; Questionnaires; Sleep; Sleep and wakefulness; sleep/wake mechanisms; Delayed Sleep-Wake Phase Disorder; night owl; Optic Nerve Hypoplasia; biological rhythms; circadian rhythm disorders; clinical trials research; sleep/wake mechanisms; delayed sleep
• ISSN: 1662-453X; 1662-4548; 1662-453X
• DOI: 10.3389/fnins.2023.1287514

We present a case of an adult female diagnosed with Delayed Sleep-Wake Phase Disorder (DSWPD) and Optic Nerve Hypoplasia (ONH), with a confirmed delayed Dim Light Melatonin Onset (DLMO), who reports the inability to fall asleep at their desired bedtime and obtain adequate sleep nightly, despite the ability to have a full night’s sleep when not required to be up at a specific time for societal requirements. The participant was enrolled in an 11-month Open-Label Extension (OLE) following the randomized portion of a clinical study and was successfully treated with tasimelteon. DSWPD symptoms were resolved, and their previously delayed sleep-wake cycle was advanced.